Cargando…
An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699239/ https://www.ncbi.nlm.nih.gov/pubmed/31489287 http://dx.doi.org/10.4103/sajc.sajc_18_19 |
_version_ | 1783444680999960576 |
---|---|
author | Talreja, Vikas T. Noronha, Vanita Joshi, Amit Patil, Vijay Mahajan, Abhishek Prabhash, Kumar |
author_facet | Talreja, Vikas T. Noronha, Vanita Joshi, Amit Patil, Vijay Mahajan, Abhishek Prabhash, Kumar |
author_sort | Talreja, Vikas T. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6699239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-66992392019-09-05 An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma Talreja, Vikas T. Noronha, Vanita Joshi, Amit Patil, Vijay Mahajan, Abhishek Prabhash, Kumar South Asian J Cancer Letter to the Editor Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6699239/ /pubmed/31489287 http://dx.doi.org/10.4103/sajc.sajc_18_19 Text en Copyright: © 2019 The South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Letter to the Editor Talreja, Vikas T. Noronha, Vanita Joshi, Amit Patil, Vijay Mahajan, Abhishek Prabhash, Kumar An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
title | An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
title_full | An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
title_fullStr | An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
title_full_unstemmed | An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
title_short | An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
title_sort | exceptional response to nivolumab in relapsed and refractory malignant mesothelioma |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699239/ https://www.ncbi.nlm.nih.gov/pubmed/31489287 http://dx.doi.org/10.4103/sajc.sajc_18_19 |
work_keys_str_mv | AT talrejavikast anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT noronhavanita anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT joshiamit anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT patilvijay anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT mahajanabhishek anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT prabhashkumar anexceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT talrejavikast exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT noronhavanita exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT joshiamit exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT patilvijay exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT mahajanabhishek exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma AT prabhashkumar exceptionalresponsetonivolumabinrelapsedandrefractorymalignantmesothelioma |